Ian Chau

Presentation(s):

• O-3: Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): expanded efficacy and safety analyses from CheckMate 648

  Thursday, June 30, 2022
  08:34 – 08:46